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Abstract: 
The recently published 2016 World Health Organization (WHO) classification of 
tumours of the Central Nervous System (CNS) introduces a number of significant 
changes from the previous edition. Based on an improved understanding of the 
genetic and molecular basis of tumorigenesis there has been a shift towards defining 
tumours by means of these characteristics in addition to their histological features, 
thus providing an integrated diagnosis. In this article, we will provide a concise 
overview of the salient changes in the 2016 WHO classification of tumours of the 
CNS that are of relevance to the paediatric neuroradiologist when it comes to day-to-
day reporting. 
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Background: 
The 2007 WHO classification of CNS tumours was primarily based on histological 
features which presented a number of issues and limitations. In comparison, the 
2016 WHO CNS tumour classification builds on developments and research in the 
molecular and genetic basis of tumorigenesis and aims to incorporate these 
molecular features alongside histological findings in tumour classification. The aim is 
to provide an integrated phenotypic and genotypic diagnosis thus more accurately 
defining real biological entities.  
By means of an integrated approach to tumour classification narrower diagnostic 
criteria can be applied resulting in improved diagnostic accuracy and a reduction in 
inter-observer variability. This in turn will hopefully improve the reproducibility of 
results and better guide prognostication and treatment of CNS tumours.  
As a result of this new method of classification, a number of new tumour entities 
have been described in this updated edition. There has also been significant 
restructuring of the classification of pre-existing tumour categories including the 
diffuse gliomas, medulloblastomas and other embryonal tumours. Entities such as 
gliomatosis cerebri have been downgraded to a pattern of spread rather than a 
distinct biological entity from the diffuse gliomas. 
The nomenclature of tumours has subsequently changed, and now for several 
tumours consists of the histopathological name followed by the genetic determinant 
e.g. medulloblastoma, SHH-activated, TP53-mutant. The not otherwise specified or 
NOS suffix is reserved for situations where there is either insufficient material or the 
facilities for testing for the specific genotype are not available. 
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In cases where there is discordance between the histology and molecular genetic 
features the pathologist needs to judge the relevance of each piece of evidence but 
in an increasing number of tumours it is the genotype that will be the primary 
determinant of the tumour type. An example of this would be a diffuse glioma that is 
histologically astrocytic but is also found to have IDH mutation and 1p/19q 
codeletion. Under the new classification this will fall under the diagnosis of 
oligodendroglioma, IDH-mutant and 1p/19q codeleted. 
A recent review by Louis et. al. provides a comprehensive overview of the changes 
that that 2016 classification brings with it(1). 
Whilst a large majority of changes relate to histological and molecular diagnostic 
criteria, an understanding of the new classification and nomenclature will be vital for 
the paediatric neuroradiologist when it comes to reporting. 
New Entities, Variants and Patterns that the Paediatric Neuroradiologist should 
be aware of including the following: 
Neuronal and mixed neuronal-glial tumours: 
A new tumour entity of neuronal-glial origin commonly presenting in childhood and 
adolescence is the diffuse leptomeningeal glioneuronal tumour. These tumours are 
characterised by predominant and widespread leptomeningeal growth with or without 
a parenchymal component. Histologically these tumours frequently have 
oligodendroglial cytology with evidence of neuronal differentiation on 
immunohistochemistry, Whilst IDH mutations are typically absent, molecular findings 
may include BRAF fusion, isolated 1p deletions or combined 1p/19q codeletions(2). 
 
5 
 
 
Medulloblastomas: 
The commonest malignant brain tumours in childhood are now defined by integrated 
diagnoses which accounts for the genetic and histological features of the tumour.  
The histological classification is already well defined and includes classic, 
anaplastic/large cell, desmoplastic/nodular and extensive nodular variants. In terms 
of molecular classification, the subtypes of include WNT-activated, SHH-activated 
and non-WNT/non-SHH (group 3 and group 4)(3). Providing an integrated diagnosis 
is of clinical value as both the histological and molecular variants have distinct 
therapeutic and prognostic implications.  
An entity of particular relevance is the medulloblastoma, SHH-activated and TP53 
mutant. It is defined by the WHO as: ‘A poorly differentiated embryonal tumour of the 
cerebellum with evidence of SHH pathway activation and either germline or somatic 
TP53 mutation’(4). The clinical outcomes for this subgroup of medulloblastoma are 
very poor. These patients carry a significant risk of having a germline TP53 mutation 
and should be offered genetic counselling. 
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Diffuse gliomas: 
This group has been restructured and now includes all the diffusely infiltrating 
gliomas regardless of whether they are astrocytic or oligodendroglial in origin. The 
restructuring is based on the genetic understanding of adult tumours, which are 
largely determined based on IDH gene mutations and the presence or absence of 
1p/19q codeletions(3). This is of limited value in paediatrics as both genetic changes 
are rare in paediatric tumours even when they are of the similar histological type to 
their adult counterparts. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow diagram for diffuse glioma classification. Adapted from Louis et. al.(1)  
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Paediatric diffuse gliomas: 
There has been separation of paediatric diffuse gliomas from adult diffuse gliomas 
based on the presence of molecular markers thus allowing for more targeted 
therapies. A new entity in this group is diffuse midline glioma, H3 K27M-mutant. 
These midline tumours (typically of the thalamus, pons or spinal cord) with a diffuse 
pattern encompass many of the tumours recognised as diffuse intrinsic pontine 
glioma (DIPG) and many high-grade gliomas of the thalamus in children. These 
tumours have a poor prognosis(5). 
Diffuse astrocytoma and anaplastic astrocytoma: 
The terms protoplasmic astrocytoma and fibrillary astrocytoma are no longer in the 
2016 classification. Gliomatosis cerebri is no longer considered a distinct entity but is 
regarded as a growth pattern of other glial tumours(4). 
Glioblastomas: 
Glioblastomas are classified based on IDH mutations into glioblastoma, IDH-wild-
type, glioblastoma, IDH-mutant and glioblastoma, NOS (4). 
One particular new entity of relevance to the paediatric neuroradiologist is the 
epitheloid glioblastoma. These tumours typically present as diencephalic or 
superficial cerebral masses. Histologically they are characterised by large epithelioid 
cells, vesicular chromatin and prominent nucleoli. Rhabdoid cells may also be 
present. Immunohistochemistry or sequencing often reveals a BRAF V600E 
mutation(6). 
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Other astrocytomas: 
Anaplastic pleomorphic xanthoastrocytoma has been added as a distinct entity as 
opposed to the previously applied descriptive title of pleomorphic xanthoastrocyomta 
with anaplastic features (4). 
Ependymomas: 
These are the third commonest neuroepithelial tumours of childhood, after 
astrocytomas and medulloblastomas. There is increasing data suggesting that 
ependymomas can be divided into several subtypes on the basis of molecular 
profiling (particularly DNA methylation profiling). 
With regards to the 2016 classification, one of the new molecularly defined entities in 
this category is ependymoma, RELA fusion-positive. RELA fused ependymomas 
constitute most of the supratentorial ependymomas encounterd in children and have 
a poor prognosis (4). 
Cellular ependymoma has been deleted in the 2016 classification. 
Other embryonal tumours: 
The term CNS-primitive neuroectodermal tumour (PNET) and supratentorial PNET 
have been removed from the diagnostic lexicon.  This will avoid confusion with the 
peripheral-type PNET or Ewing’s sarcoma that can still present with the skull or 
occasionally the CNS (1). 
There has been a major restructuring of the classification of non-medulloblastoma 
embryonal tumours particularly taking account of a subgroup that display 
amplification of the C19MC region encoding an miRNA cluster of chromosome 19 
(19q.13.42).  
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The entity previously recognised as embryonal tumour with abundant neuropil and 
true rosettes (ETANTR) or embryonal tumour with multilayered rosettes (ETMR), 
ependymoblastoma and most cases of medulloepithelioma have been reclassified 
based on the presence or absence of C19MC amplification (7). 
In cases of confirmed C19MC amplification, the term embryonal tumour with 
multilayered rosettes (ETMR), C19MC-altered should be applied. Most of the 
tumours previously described as medulloepithelioma will now be classified as ETMR, 
C19MC-alterated. Tumours without the C19MC alteration will be classified under the 
category of medulloepthelioma (1). 
Atypical teratoid / rhabdoid tumour (AT/RT) is now characterised by alterations in 
SMARCB1 (INI1) or rarely SMARCA4 (BRG) CNS embryonal tumour with rhabdoid 
features is used for tumours that have histological features of AT/RT without the 
specific genetic alterations (4, 8, 9). 
There remain a group of embryonal tumours of the nervous system that do not have 
one of these characteristic features and these are described as CNS neuroblastoma, 
CNS ganglioneuroblastoma or embryonal tumour, NOS depending on the 
histological findings. However, it should be noted that some of the tumours 
historically described in this group can be reclassified into other tumour entities 
based on current diagnostic techniques (e.g. high grade glioma, ETMR, AT/RT and 
ependymoma) and these alternative diagnoses need to be actively excluded before 
a diagnosis of embryonal tumour is accepted.  
There are some exciting new molecular data that indicate that there are new tumour 
entities that account for a number of the embryonal tumours and it is likely that future 
classifications will take account of these new CNS tumours (10). 
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Conclusion: 
The 2016 WHO classification of CNS tumours introduces a number of significant 
changes, a large proportion of which relate to an improved understanding of the 
molecular and genetic basis of tumorigenesis. It is vital that the paediatric 
neuroradiologist is familiar with the new nomenclature, classification, patterns of 
spread and reclassification of entities that are no longer considered relevant as all 
these factors have implications with regards to patient management and 
prognostication. Whilst diagnoses can still be made for tumour variants that fall into a 
NOS category, ongoing research will hopefully enable further characterisation of 
these entities which are not yet fully defined. 
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